Advertisement

The Role of the c-fos Oncogene in Cisplatin Resistance

  • L. Jiao
  • T. Funato
  • W. Wang
  • T. Tone
  • M. Kashani-Sabet
  • K. J. Scanlon

Abstract

The c-fos oncogene has been proposed to play an important role not only in DNA synthesis (1) but also in resistance to the antineoplastic agent cis-diamminedichloroplatinum (cisplatin) (2). Administration of cisplatin to A2780 ovarian carcinoma cells was followed by a sequential induction of c-fos, dTMP synthase, and DNA polymerase. A2780 cells transfected with a plasmid containing the fos gene displayed morphological and pharmacological changes reflecting cisplatin resistance. A ribozyme (catalytic RNA) was designed to cleave c-fos mRNA. Cleavage conditions were optimized in vitro, and DNA encoding the fos ribozyme was cloned into the pMAMneo expression vector. The resultant plasmid was transfected into the A2780DDP cell line resistant to cisplatin, and the transformants assayed for enhanced sensitivity to cisplatin. These results suggest that c-fos plays a causal role in cisplatin resistance.

Keywords

A2780 Cell 60mm Tissue Culture Dish A2780S Cell A2780DDP Cell Thymidine Triphosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Riabowol, K.T., Vosatka, R.J., Ziff, E.B., Lamb, N.J., and Feramisco, J.R. Mol. Cell. Biol. 8,1670 (1670).Google Scholar
  2. 2.
    Scanlon, K.J., Kashani-Sabet, M., Miyachi, H., Sowers, L, and Rossi, J. Anticancer Res. 9,1301 (1301).Google Scholar
  3. 3.
    Curran, T., and Franza Jr., B.R. Cell 55,395 (1988).PubMedCrossRefGoogle Scholar
  4. 4.
    Greenberg, M.E. and Ziff, E.B. Nature (Lorfdon) 311, 433 (1984).CrossRefGoogle Scholar
  5. 5.
    Kashani-Sabet, M., Wang, W. and Scanlon, K.J. J. Biol. Chem. 265,11285 (1990).PubMedGoogle Scholar
  6. 6.
    Hollander, M.C. and Fornace, A.J. Cancer Res. 49,1687 (1989).PubMedGoogle Scholar
  7. 7.
    Scanlon, K.J., Kashani-Sabet, M., and Sowers, L. Cancer Comm. 1,269 (1989).Google Scholar
  8. 8.
    Kashani-Sabet, M., Lu, Y., Leong, L., Haedicke, K., and Scanlon, K.J. Eur. J. Cancer 26,383 (1990).PubMedCrossRefGoogle Scholar
  9. 9.
    Lu, Y., Han, J., and Scanlon, K.J. J. Biol. Chem. 263,4891 (4891).Google Scholar
  10. 10.
    Scanlon, K.J. and Kashani-Sabet, M. Proc. Natl. Acad. Sci. (USA) 85,650 (1988).CrossRefGoogle Scholar
  11. 11.
    Chang, P.S. et. al. Clin. Biotech. 2,23 (1990).Google Scholar
  12. 12.
    Haseloff, J. and Gerlach, W.L. Nature (London) 334, 585 (1988).CrossRefGoogle Scholar
  13. 13.
    Scanlon, K.J. et al., manuscript submitted.Google Scholar
  14. 14.
    Scanlon, K.J., Lu, Y., Kashani-Sabet, M., Ma, J.-X., and Newman, E. In The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy, Y. Rustum, J. McGuire, eds. Plenum Press, New York, 1988, 244, 127 (1988).Google Scholar
  15. 15.
    Schönthal, A., Herrlich, P., Rahmsdorf, H.J., and Ponta, H. Cell 54,325 (1988).PubMedCrossRefGoogle Scholar
  16. 16.
    Rauscher III, F.J., Sambucetti, L.C., Curran, T., Distell, R.J., and Spiegelman, B.M. Cell 52,471 (1988).PubMedCrossRefGoogle Scholar
  17. 17.
    Kelley, S. et. al. Science 241,1813 (1813).CrossRefGoogle Scholar
  18. 18.
    Abate, C, Luk, D., Gentz, R., Rauscher III, F.J., and Curran, T. Proc. Natl. Acad. Sci. (USA) 87,1032 (1032).CrossRefGoogle Scholar
  19. 19.
    Sklar, M.D. Cancer Res. 48,793 (1988).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • L. Jiao
    • 1
  • T. Funato
    • 1
  • W. Wang
    • 1
  • T. Tone
    • 1
  • M. Kashani-Sabet
    • 1
  • K. J. Scanlon
    • 1
  1. 1.Biochemical Pharmacology, Department of Medical OncologyCity of Hope National Medical CenterDuarteUSA

Personalised recommendations